Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library

Infection with SARS‐CoV‐2 elicits robust antibody responses in some patients, with a majority of the response directed at the receptor binding domain (RBD) of the spike surface glycoprotein. Remarkably, many patient‐derived antibodies that potently inhibit viral infection harbor few to no mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Benjamin N., Powell, Abigail E., Rodriguez, Carlos, Cochran, Jennifer R., Kim, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Accelerated Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980507/
https://www.ncbi.nlm.nih.gov/pubmed/33586288
http://dx.doi.org/10.1002/pro.4044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980507/
https://www.ncbi.nlm.nih.gov/pubmed/33586288
http://dx.doi.org/10.1002/pro.4044

Ejemplares similares